【ENCell Co., Ltd., Spin-off Company of Samsung Medical Center】
Through the operation of 3 separate GMP facilities, ENCell has the full capability and capacity to carry out both cell (stem cells, CAR-T, NK cells, exosomes) and gene (lentivirus, AAV) therapy manufacturing as a one-stop service for our clients. All of our GMP facilities adhere to the stringent PIC/S regulations and hold requisite licensure in South Korea to manufacture advanced biopharmaceutical products. To date there are 26 completed and ongoing projects, including contract manufacturing of investigational drug products, that we have or are still working for a total of 16 clients. Five phase 1 trials have been completed and a total of 10 IND applications have been granted approval, including IND approval of an exosome product by the US FDA.